Document:

EX-10.2

 Exhibit 10.2 

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

AMENDMENT #2 TO 

LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT 

This Amendment #2 to LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (“Amendment”), is entered into between Syndax Pharmaceuticals,
Inc., a Delaware corporation having a place of business at 400 Totten Pond Road, Suite 110, Waltham, MA 02451 USA (“Syndax”) and Kyowa Hakko Kirin Co., Ltd., a Japanese corporation having a place of business at 1-9-2, Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan (“KHK”), effective as of
January 16, 2017 (the “Amendment Effective Date”). 
 Reference is made to that the LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by
and between Syndax and KHK entered into as of December 19, 2014 (“Agreement”), as previously amended. As of the Amendment Effective Date, the Agreement is hereby further amended as set forth in this Amendment. Capitalized terms
used but not defined herein shall have the meanings assigned to such terms in the Agreement. 
 The parties agree that the following new sentences are
hereby added at the end of Section 4.4: 
 “Syndax shall use best efforts to ensure that a laboratory *** at the Medical Oncology
Branch, Center for Cancer Research, National Cancer Institute (“NCI”), which has performed or is performing analyses of blood samples from one or more Clinical Trials on Entinostat for Syndax under the Cooperative Research and Development
Agreement #836 “Preclinical and Clinical Development of MS-275 (NSC-706995), a Histone Deacetylase Inhibitor, as an Anti-Cancer Agent” (CRADA), will, pursuant
to KHK’s request, perform analyses of blood samples from one or more Territory Trials in Japan on Entinostat being conducted by KHK (or its licensees) and provide to KHK the data developed or generated therefrom. Unless otherwise agreed upon
between Syndax and KHK, the cost of such analyses of blood samples to be paid to NCI shall be the following: 
  

	 	(a)	Total cost will be USD *** for *** samples. If the number of sample is more than *** samples, additional costs will be USD *** per sample. 

 

	 	(b)	Syndax will pay to NCI USD *** as an initial payment upon the execution of the amendment #12 of the CRADA with NCI. Syndax will pay to NCI the remaining cost, USD *** plus the additional costs for more than *** samples
(if necessary), when NCI has completed the measurement. 

  

	 	(c)	The total cost shall not exceed USD *** without the express written consent of Syndax and KHK. 

 Further,
Syndax shall use best efforts to ensure that NCI will keep the documents of the results for and on behalf of KHK at least for *** after the end of such blood sample analyses. 

Subject to the foregoing, the cost of such work for analyses of blood samples from the Territory Trials and document retention will be borne by KHK using the
following procedure: 
 Payment for such support will be *** in connection with performing such analyses and document retention, due on a ***. Syndax will
pay to NCI the *** for such work, and KHK agrees to reimburse Syndax for such cost no later than *** after receipt of invoice(s) detailing same. Unless otherwise agreed between Syndax and KHK, the maximum amount to be reimbursed by KHK shall be USD
***.” 

 All other terms, obligations and conditions of the Agreement shall remain in full force and effect. 

This Amendment may be executed in one or more counterparts by the parties by a person having authority to bind the party, each of which when executed and
delivered by facsimile, electronic transmission or by mail delivery, will be an original and all of which shall constitute but one and the same Amendment. 
  

									
	Syndax Pharmaceuticals, Inc.	 		 	Kyowa Hakko Kirin Co., Ltd.
					
	By:	 	 /s/ Allan Shaw
	 		 	By:	 	 /s/ Tamao Watanabe

					
	Name:	 	Allan Shaw	 		 	Name:	 	Tamao Watanabe
					
	Title:	 	CFO	 		 	Title:	 	Effective Officer,
		 		 		 		 	Director,
		 		 		 		 	Head of Business Development Department
					
	Date:	 	January 18, 2017	 		 	Date:	 	January 16, 2017

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

  
 2EX-10.3

 Exhibit 10.3 

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

AMENDMENT NO. 8 TO 

CLINICAL TRIAL AGREEMENT 

BETWEEN 
 ECOG-ACRIN
CANCER RESEARCH GROUP 
 AND SYNDAX PHARMACEUTICALS, INC. 

This Amendment No. 8 to Clinical Trial Agreement (the “Amendment” or “Amendment 8”) is entered into as of January 18, 2017 (the
“Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals,
Inc. (“Company” or “Syndax”). 
 WITNESSETH: 

WHEREAS, pursuant to the Clinical Trial Agreement dated March 14, 2014 between the parties (“Agreement”), the parties agreed to
certain terms specified therein for research services related to Group’s performance of the Study; and 
 WHEREAS, the parties agree to
increase the support for the Study to cover budget support to partially offset the expenses associated with *** for the Study as set forth herein. 
 NOW,
THEREFORE, the parties hereto, intending to be legally bound hereby, agree as follows: 
  

	A.	The following is added to Section 1.G of the Agreement: 

 The Company will provide financial
support to the Group in the amount of $1,582,064 to support the activities for the *** for the Study as set forth in Exhibit D. The maximum financial support for the Agreement is increased from $21,866,506 by $1,582,064 to $23,448,570. 

 

	B.	Exhibit B of the Agreement is deleted in its entirety and replaced by Exhibit B attached hereto. 

  

	C.	Exhibit D attached hereto is hereby added as Exhibit D of the Agreement thereto. 

  

	D.	This Amendment constitutes the full understanding of the parties and a complete and exclusive statement of the terms of their agreement with respect to the subject matter described herein, and no terms, conditions,
understanding, or agreement purporting to modify or vary the terms of this Amendment shall be binding unless made in writing and signed by the parties. 

  

	E.	This Amendment 8 may be terminated by the joint written agreement of the Company and the Group if the work being performed by the Group pursuant to this Amendment 8 is considered complete. 

	F.	Except to the extent amended herein, all of the terms and conditions of the Agreement remain in full force and effect. 

  

	G.	Capitalized terms herein that are not defined shall have the meaning ascribed to such terms in the Agreement. 

  

	H.	This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which shall be considered one and the same instrument. 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment, as of the Effective Date, by proper persons duly authorized. 

 

									
	ECOG-ACRIN Cancer Research Group	 		 	Syndax Pharmaceuticals, Inc.
			
	 /s/ Robert L. Comis
	 		 	 /s/ Luke J. Albrecht

	Name:	 	Robert L. Comis, M.D.	 		 	Name:	 	Luke J. Albrecht
	Title:	 	Group Co-Chair	 		 	Title:	 	Vice President, General Counsel

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

  
 2 

 EXHIBIT B 

E2112 Budget & Payment Schedule 
  

	A.	Budget Details 

  

	1.	Budget – Excluding Amendments 

 The budget for this project is $19,406,948 which is itemized as follows:

 *** 
  

	2.	Budget – Amendment 1 

 The budget for Amendment 1 is $1,200,000 which is itemized as follows: 

*** 
  

	3.	Budget – Amendment 3 

 The budget for Amendment 3 (*** Support) is $450,000 which is itemized as follows:

 *** 
  

	4.	Budget – Amendment 4 

 The budget for Amendment 4 (***) is $7,908 which is itemized as follows: 

*** 
  

	5.	Budget – Amendment 5 

 The budget for Amendment 5 is $30,121 which is itemized as follows: 

*** 
 *** services being provided through Amendment 5 is limited
to *** of *** services plus *** of Group ***. 
  

	6.	Budget – Amendment 6 

 The budget for Amendment 6 is $287,438 which is itemized as follows: 

*** 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

  
 3 

	7.	Budget – Amendment 7 

 The budget for Amendment 7 is $484,091 which is itemized as follows: 

*** 
  

	8.	Budget – Amendment 8 

 The budget for Amendment 8 is $1,582,064 which is itemized as follows: 

*** 
  

	9.	Invoicing and Payments 

 Company will make payments within *** of receipt of invoices from Group according to
the Payment Schedule herein. Payments will be made to as set forth in Section 1.B of the Agreement as follows: 
 ECOG Research and
Education Foundation, Inc. 
 Agent for ECOG-ACRIN Cancer Research Group 

Attn: Donna Marinucci 
 1818
Market Street, Suite 1100 
 Philadelphia, PA 19103 

Group will send invoices to the following address: 

Jeannette Hasapidis 
 VP,
Clinical Operations 
 Syndax Pharmaceuticals, Inc. 

400 Totten Pond Road, Suite 110 

Waltham, MA 02451 
  

	B.	Payment Schedule – Excluding Amendments 

 Group will submit invoices to Company in accordance with
the following Payment Schedule: 
 *** 
  

	C.	Payment Schedule – Amendment 1 

 Group will submit invoices to Company in accordance with the
following Payment Schedule: 
 *** 
  

	D.	Payment Schedule – Amendment 3 (***) 

 Group will submit invoices to Company in accordance with the
following Payment Schedule: 
 *** 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

  
 4 

	E.	Payment Schedule – Amendment 4 

 Group will submit invoices to Company in accordance with the
following Payment Schedule: 
 *** 
  

	F.	Payment Schedule – Amendment 5 

 Group will submit invoices to Company in accordance with the
following Payment Schedule: 
 *** 
  

	G.	Payment Schedule – Amendment 6 

 Group will submit invoices to Company in accordance with the
following Payment Schedule: 
 *** 
  

	H.	Payment Schedule – Amendment 7 

 Group will submit invoices to Company in accordance with the
following Payment Schedule: 
 *** 
  

	I.	Payment Schedule – Amendment 8 

 Group will submit invoices to Company in accordance with the
following Payment Schedule: 
 *** 

  
 *** INDICATES MATERIAL THAT WAS
OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. 

  
 5 

 EXHIBIT D 

E2112 Scope of Work – Amendment 8 

(*** Services) 
 Protocol
Title: A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Post- menopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer 

*** 

  
 *** INDICATES 1 PAGE OF MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]